PHOENIX, July 17, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire, today announced the interview of Avivagen Chairman and CEO Kym Anthony on Stock Day Podcast with Everett Jolly.

Avivagen’s scientifically backed, evidence-based products are in high demand from veterinarians, farmers and producers, pet owners and retailers.  The Company now has regulatory approval in multiple countries, including Canada, China, and Thailand. “I would like you to update us on your new contracts with New Zealand, the Chinese government and the Philippines,” said Jolly.  “What has transpired since the last time you were on the show?”

“There have been many interesting developments moving from being an R&D company to being a commercial company,” said Anthony.  “Usage of our product in the Philippines has grown to between 800 kg to a ton per month.”

“In January we released new applications for our products, we had a really striking set of trials conducted in China and the Philippines,” Anthony continued.  “Additionally, in May of this year we announced the approval of our products for all applications, livestock and companion animals by New Zealand, which has a very large dairy industry.” 

Avivagen is focusing on both client development and regulatory development; and is now in the application process in Mexico, Vietnam, South Korea, Brazil, Russia and the United States.  “The relationships we have are sticky,” said Anthony.  “We are going in the right direction for profitability.”

To listen to the full interview please click here to the following link: https://upticknewswire.com/featured-interview...k-chexf-3/

About Avivagen Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit  www.avivagen.com . The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the expectation that UNAHCO will continue to order product at the current rate or increase orders, the possibility for deployment or launch of OxC-beta™ Livestock in new jurisdictions around the world or for it to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded, Avivagen’s intention to accelerate market access and the commercial uptake of its OxC-beta™ Livestock product and the size of market opportunities are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, UNAHCO is under no obligation to continue purchasing product from Avivagen or to increase its purchases and it could cease or reduce its purchases at any time, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen and the market opportunities may not be as large as Avivagen anticipates due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information: Avivagen Inc. Drew Basek Director of Investor Relations 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733 E-mail:  d.basek@avivagen.com

Kym Anthony Chairman & Interim CEO 100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164 Website:  www.avivagen.com

About Uptick Newswire and the “Stock Day” Podcast Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona.

Source:  Uptick Newswire

Investors Hangout  is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit Avivagen, message board on:  https://investorshangout.com/